Literature DB >> 22551294

Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines.

Peter Ochodnický1, Sian Humphreys, Rachel Eccles, Mirjana Poljakovic, Peter Wiklund, Martin C Michel.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? Urothelium emerged as a crucial integrator of sensory inputs and outputs in the bladder wall, and urothelial G-protein-coupled receptors (GPCRs) may represent plausible targets for treatment of various bladder pathologies. Urothelial cell lines provide a useful tool to study urothelial receptor function, but their validity as models for native human urothelium remains unclear. We characterize the mRNA expression of genes coding for GPCRs in human freshly isolated urothelium and compare the expression pattern with those in human urothelial cell lines.
OBJECTIVES: To characterize the mRNA expression pattern of genes coding for G-protein-coupled receptors (GPCRs) in human freshly isolated urothelium. To compare GPCR expression in human urothelium-derived cell lines to explore the suitability of these cell lines as model systems to study urothelial function.
MATERIALS AND METHODS: Native human urothelium (commercially sourced) and human urothelium-derived non-cancer (UROtsa and TERT-NHUC) and cancer (J82) cell lines were used. For mRNA expression profiling we used custom-designed real-time polymerase chain reaction array for 40 receptors and several related genes.
RESULTS: Native urothelium expressed a wide variety of GPCRs, including α(1A), α(1D) and all subtypes of α(2) and β adrenoceptors. In addition, M(2) and M(3) cholinergic muscarinic receptors, angiotensin II AT(1) receptor, serotonin 5-HT(2A) receptor and all subtypes of bradykinin, endothelin, cannabinoid, tachykinin and sphingosine-1-phosphate receptors were detected. Nerve growth factor and both its low- and high-affinity receptors were also expressed in urothelium. In all cell lines expression of most GPCRs was markedly downregulated, with few exceptions. In UROtsa cells, but much less in other cell lines, the expression of β(2) adrenoceptors, M(3) muscarinic receptors, B(1) and B(2) bradykinin receptors, ET(B) endothelin receptors and several subtypes of sphingosine-1-phosphate receptors was largely retained.
CONCLUSIONS: Human urothelium expresses a wide range of receptors which enables sensing and integration of various extracellular signals. Human urothelium-derived cell lines, especially UROtsa cells, show comparable mRNA expression to native tissue for several physiologically relevant GPCRs, but lose expression of many other receptors. The use of cell lines as model systems of human urothelium requires careful validation of suitability for the genes of interest.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551294     DOI: 10.1111/j.1464-410X.2012.011145.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

1.  Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium.

Authors:  Saqib Shabir; William Cross; Lisa A Kirkwood; Joanna F Pearson; Peter A Appleby; Dawn Walker; Ian Eardley; Jennifer Southgate
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-29

2.  Human urothelial cell lines as potential models for studying cannabinoid and excitatory receptor interactions in the urinary bladder.

Authors:  Evangelia Bakali; Ruth A Elliott; Anthony H Taylor; David G Lambert; Jonathon M Willets; Douglas G Tincello
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-21       Impact factor: 3.000

3.  Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release.

Authors:  Giselle Bravo; Helen Massa; Roselyn Rose'Meyer; Russ Chess-Williams; Catherine McDermott; Donna J Sellers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

Review 4.  β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Authors:  Yasuhiko Igawa; Naoki Aizawa; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

Review 5.  Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium.

Authors:  Donna Sellers; Russ Chess-Williams; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-28       Impact factor: 3.000

6.  Specificity evaluation of antibodies against human β3-adrenoceptors.

Authors:  Hana Cernecka; Peter Ochodnicky; Wouter H Lamers; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06-12       Impact factor: 3.000

Review 7.  G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets.

Authors:  Paul A Insel; Andrea Wilderman; Alexander C Zambon; Aaron N Snead; Fiona Murray; Nakon Aroonsakool; Daniel S McDonald; Shu Zhou; Thalia McCann; Lingzhi Zhang; Krishna Sriram; Amy M Chinn; Alexander V Michkov; Rebecca M Lynch; Aaron C Overland; Ross Corriden
Journal:  Mol Pharmacol       Date:  2015-03-03       Impact factor: 4.436

8.  Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.

Authors:  Yasuhiko Igawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-21       Impact factor: 3.000

9.  NKA enhances bladder-afferent mechanosensitivity via urothelial and detrusor activation.

Authors:  Luke Grundy; Russ Chess-Williams; Stuart M Brierley; Kylie Mills; Kate H Moore; Kylie Mansfield; Roselyn Rose'Meyer; Donna Sellers; David Grundy
Journal:  Am J Physiol Renal Physiol       Date:  2018-06-13

10.  M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells.

Authors:  Luca Pacini; Elena De Falco; Maria Di Bari; Andrea Coccia; Camilla Siciliano; Donatella Ponti; Antonio Luigi Pastore; Vincenzo Petrozza; Antonio Carbone; Ada Maria Tata; Antonella Calogero
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.